Phase I, Dose-escalating, Clinical and Pharmacokinetic Study of Humanized Сhimeric Anti-CD47 Antibody in Patients With Verified Diagnosis of Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2015
At a glance
- Drugs CC 90002 (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Acronyms ASSIST-II
- 10 Jun 2017 Biomarkers information updated
- 31 Aug 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
- 27 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Aug 2015, according to ClinicalTrials.gov record.